Spyre Therapeutics | 424B3: Prospectus
Spyre Therapeutics | 8-K/A: Current report (Amendment)
Spyre Therapeutics | 8-K: Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Spyre Therapeutics | 10-Q: Q2 2024 Earnings Report
Spyre Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-FMR LLC(12.963%),Abigail P. Johnson(12.963%)
Spyre Therapeutics | 8-K: Current report
Spyre Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Stelzer Laurie
Spyre Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Albers Jeffrey W.
Spyre Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Milligan Sandra
Spyre Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Fairmount Funds Management LLC
Spyre Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director HENDERSON MICHAEL THOMAS
Spyre Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Milligan Sandra
Spyre Therapeutics | 424B3: Prospectus
Spyre Therapeutics | 8-K: Current report
Spyre Therapeutics | 8-K: Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Spyre Therapeutics | 10-Q: Q1 2024 Earnings Report
Spyre Therapeutics | EFFECT: Others
Spyre Therapeutics | CORRESP: CORRESP
Spyre Therapeutics | UPLOAD: Others
Spyre Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Fairmount Funds Management LLC
No Data